[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368796-105":59,"doc-detail-368796-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sepsis-detection-in-hematologic-and-solid-tumor-malignancies-using-quantitative-inflammatory-biomarker-differences-in-a-prospective-single-center-study","Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study","","Sepsis is a life-threatening condition driven by a dysregulated immune response to bloodstream infection, and malignancy patients face elevated risk of severe infection and sepsis onset. This prospective observational single-center study evaluates whether quantitative inflammatory biomarkers can distinguish sepsis in hematologic versus solid tumor patients. Hematologic cancer patients show significantly higher IL-6, PCT, and MON at sepsis onset, with AUC values above 0.75. In solid tumor cases, biomarker changes are more limited, including moderate PCT elevation without statistical significance. The results highlight the need for cancer-specific sepsis diagnostic strategies reflecting distinct immune dynamics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sepsis-detection-in-hematologic-and-solid-tumor-malignancies-using-quantitative-inflammatory-biomarker-differences-in-a-prospective-single-center-study/368796/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sepsis-detection-in-hematologic-and-solid-tumor-malignancies-using-quantitative-inflammatory-biomarker-differences-in-a-prospective-single-center-study/368796.png","ImageObject",300,407,{"name":92,"@type":93},"Mimi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"The study evaluates the efficacy of quantitative inflammatory biomarkers for distinguishing sepsis in patients with hematologic and solid tumors.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which biomarkers performed best in hematologic cancer patients with sepsis?",{"text":117,"@type":113},"Hematologic cancer patients showed significantly elevated IL-6, PCT, and MON, with AUC values exceeding 0.75, indicating strong predictive value.",{"name":119,"@type":110,"acceptedAnswer":120},"Did biomarkers significantly differentiate sepsis in solid tumor patients?",{"text":121,"@type":113},"The difference was not statistically significant in solid cancer patients with sepsis; for example, PCT showed only moderate, non-significant increase (AUC = 0.693).","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368796,1790545353,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study  \nDaniela Carcò1, Valeria Iachelli2, Uros Markovic3, Giulia Chisari1,4, Federica Galbo1, Dorotea Sciacca1, Luca Giaimi1, Paolo Castorina1,5,6 & Emanuele Martorana1􀀍  \nSepsis is a life-threatening condition triggered by a dysregulated immune response to bloodstream infection. Patients with solid and hematologic malignancies are at increased risk of severe infections and the onset of sepsis. Due to the limitations of blood cultures, particularly in culture-negative sepsis, multiple serological biomarkers, such as C-reactive protein (CRP), interleukin-6 (IL-6), procalcitonin (PCT), white blood cells (WBC), lymphocytes (LYM), neutrophils (NEU), and monocytes (MON), are frequently used to diagnose infections. This prospective observational study aims to evaluate the efficacy of these biomarkers in distinguishing sepsis in patients with hematologic and solid tumors. It was observed that hematologic cancer patients exhibited significantly elevated IL-6, PCT, and MON levels, indicating their strong potential for sepsis detection. However, this difference was not statistically significant in patients with solid cancers and sepsis. Specifically, patients with blood cancer at the onset of sepsis have elevated levels of IL-6, PCT and MON, with AUCs exceeding 0.75, indicating strong predictive value. In contrast, patients with solid tumors had a moderate but not statistically significant increase in PCT (AUC = 0.693). Biomarker combinations enhanced the diagnostic power for hematologic cancers, but their performance in solid tumors remained limited. The findings underscore the need for cancer-specific sepsis diagnostic approaches, with a particular focus on the unique immune dynamics of hematologic versus solid tumors.  \nKeywords Hematologic cancer, Solid cancer, Sepsis, Serum biomarkers, Composite biomarker index  \nPatients with solid and hematologic cancers are at increased risk of severe infections and the onset of sepsis1. Septicemia is characterized as a life-threatening condition resulting from organ dysfunction triggered by adysregulated immune response to infection1. This condition can be identified in two scenarios: (1) if sepsis is explicitly documented as the primary diagnosis upon hospital admission or (2) if the primary diagnosis at admission is an infection accompanied by organ dysfunction, as indicated by a Sequential Organ Failure Assessment (SOFA) score of 2 or higher, according to the criteria established by the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)2–4. To enhance clinical applicability in every-day settings, a qSOFA assessment was developed, indicating organ dysfunction with a qSOFA > 2 1,3–5.  \nThis infection-related complication, especially prevalent among patients suffering from hematologic malignancies, is generally caused by both the immunosuppressive effects inherent to the cancer itself and the immunosuppressive nature of cancer treatments such as chemotherapy6,7.  \nPatients who meet the criteria for the SOFA score are expected to have a mortality rate exceeding 10% 8. Early identification and proper treatment of sepsis can help lower both mortality and morbidity. Several tests are available to detect sepsis and monitor its progression9. Owing to the limitations of blood cultures in diagnosing  \n1Istituto Oncologico del Mediterraneo, Viagrande, Italy. 2Laboratorio di Patologia Clinica, Azienda Sanitaria Provinciale, Siracusa, Italy. 3Division of Hematology, Azienda Ospedaliero Universitaria Policlinico “G. RodolicoSan Marco”, Catania, Italy. 4Università degli Studi di Catania, Catania, Italy. 5Istituto Nazionale Fisica Nucleare, Catania, Italy. 6Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic. 􀀍 email: [emanuele@m","cbCaiayV6ahNugbC","https://ap.wps.com/l/cbCaiayV6ahNugbC","pdf",5345965,14,"English","# Introduction\n## Biomarkers and diagnostic limitations\n# Methods and criteria\n## Sepsis-3 and qSOFA\n# Findings\n## Hematologic cancers\n## Solid tumors\n# Implications","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"The study evaluates the efficacy of quantitative inflammatory biomarkers for distinguishing sepsis in patients with hematologic and solid tumors.\"},{\"question\":\"Which biomarkers performed best in hematologic cancer patients with sepsis?\",\"answer\":\"Hematologic cancer patients showed significantly elevated IL-6, PCT, and MON, with AUC values exceeding 0.75, indicating strong predictive value.\"},{\"question\":\"Did biomarkers significantly differentiate sepsis in solid tumor patients?\",\"answer\":\"The difference was not statistically significant in solid cancer patients with sepsis; for example, PCT showed only moderate, non-significant increase (AUC = 0.693).\"}]","Sepsis detection in hematologic and solid tumor malignancies using quantitative inflammatory biomarker differences in a prospective single center study | PDF",1790178588,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9fd925565515587008453a387ff2c1c1.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06c1f092402683dec71b667feb2ff4dc.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b39c0c93147bd40d1272cfe6edff5e3.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/58c8f479b843d1c2d8b5956d28fb8aea.webp",980,1287]